Stocks · News reference
Genmab shares are trading lower after the company and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study. The study did not meet its primary endpoint.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 8:18 PM
- Checked
- Jul 23, 2026, 8:18 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.
Read original at benzingaGenmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est
Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.
Read original at benzinga